Semaglutide

Adult: As an adjunct to diet and exercise: Monotherapy (if metformin is considered inappropriate due to contraindications or intolerance) or in combination with other antidiabetic agents: Initially, 3 mg once daily for 1 month, then increase dose to 7 mg once daily for at least 1 month. If additional glycaemic control is necessary, may further increase dose up to Max of 14 mg once daily. Take one 14 mg tab to achieve the 14 mg dose; taking two 7 mg tab to reach the 14 mg dose is not recommended.

Adult: As an adjunct to diet and exercise to improve glycaemic control or to reduce the risk of major CV events: Monotherapy (if metformin is considered inappropriate due to contraindications or intolerance) or in combination with other antidiabetic agents: Ozempic Initially, 0.25 mg once weekly for 4 weeks, then increase to 0.5 mg once weekly for at least 4 weeks. If glycaemic control is inadequate after at least 8 weeks of starting the treatment, may further increase dose to 1 mg once weekly. If additional glycaemic control is needed after at least 4 weeks on the 1 mg dosage, may further increase the dose up to Max of 2 mg once weekly. Doses are injected at any time of the day, on the same day each week, with or without meals. If changing the day of weekly administration is necessary, allow at least 2 or 3 days (>48 or >72 hours) between 2 doses. Dosing recommendations may vary between countries (refer to specific product guidelines).

Adult: As an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance in patients with an initial BMI of ≥30 kg/m² (obesity) or ≥27-<30 kg/m² (overweight) in the presence of at least 1 weight-related comorbidity (e.g. hypertension, dyslipidaemia, dysglycaemia, obstructive sleep apnoea) and to reduce the risk of major adverse CV events in patients with established CV disease and either obesity or overweight: Wegovy To reduce the risk of gastrointestinal symptoms, doses are escalated over a 16-week period up to achieving a maintenance dose. Dose escalation schedule: Week 1-4: 0.25 mg once weekly; Week 5-8: 0.5 mg once weekly; Week 9-12: 1 mg once weekly; Week 13-16: 1.7 mg once weekly; Week 17 and thereafter (maintenance dose): 2.4 mg once weekly. Doses are injected at any time of the day, on the same day each week, with or without meals. If changing the day of weekly administration is necessary, allow at least 2 or 3 days (>48 or >72 hours) between 2 doses. Reassess patients if unable to lose at least 5% of their initial body weight after 6 months of treatment.
Child: ≥12 years As an adjunct to a reduced-calorie diet and increased physical activity for weight management in patients with obesity (BMI at the ≥95th percentile standardised for age and sex) and body weight >60 kg: Wegovy Same as adult dose. Dosing and treatment recommendations may vary between countries (refer to specific product guidelines).